Megan Garlapow, PhD

All articles by Megan Garlapow, PhD

• Newborn becomes first documented patient to have both HDFN and FNAIT

  Genetic and antibody testing in a newborn resulted in dual diagnoses of HDFN and FNAIT, which required prompt, coordinated treatment.

• Genetic insights could help prevent fetal intracranial hemorrhage

  A recent study showed that fetal intracranial hemorrhages often involve a wide array of genetic abnormalities beyond known mutations.

• Rallybio’s potential FNAIT treatment enters phase 2 trial

  A Phase 2 clinical trial is underway to evaluate the safety and pharmacokinetics of RLYB212, a monoclonal antibody treatment for preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT) in pregnant women at higher risk for alloimmunization, according to study information posted recently on ClinicalTrials.gov.  RLYB212 has the potential to significantly reduce risks to both mothers and […]

• Non-invasive testing could help predict infant blood groups

  Non-invasive prenatal testing has enhanced safety and accuracy for alloimmunized pregnancies, including in those with FNAIT and HDFN.

• New hemolysis tests could improve safety of IVIG treatments

  In a recent study, functional assays more accurately assessed hemolysis risks in IVIG products, which are a frontline treatment in FNAIT.

• New therapy shows early promise in preventing FNAIT

  Preclinical data from Rallybio suggested that RLYB212 may prevent fetal and neonatal allo-immune thrombocytopenia in high-risk pregnancies.

• Study: Optimizing platelet transfusions improved preterm infant outcomes

  In a recent study, a 10 mL/kg standardized dose for platelet transfusions reduced neonatal platelet exposure without increasing risks.

• Study: HLA-matched platelet transfusions showed highest success rate

  Comprehensive care strategies could improve outcomes for patients experiencing platelet transfusion refractoriness.

• Utilizing immune cell ratios could improve pregnancy outcomes

  A specific immune cell ratio may be able to predict pregnancy outcomes in women with recurrent pregnancy loss.